9. Breier A, Su TP, Saunders RC, et al. Schizophrenia is associated 25.
with elevated amphetamine induced synaptic dopamine
concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569 –2574. 26.
10. Ginovart N, Farde L, Haldin C, Swahn CG. Changes in striatal
D2-density following chronic treatment with amphetamine as- sessed with PET in nonhuman primates. Synapse 1999;31:
154 –162.
27.
11. Firnau G, Sood S, Chirakal R, et al. Cerebral metabolism of
6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate.
J Neurochem 1987;48:1077–1082.
28.
12. Nahmias C, Garnett ES, Firnau G, Lang A. Striatal dopamine
distribution in parkinsonian patients during life. J Neurol Sci
1985;69:223–230.
13. Brooks DJ, Ibanez V, Sawle GV, et al. Differing pattern of
striatal 18F-dopa uptake in Parkinson's disease, multiple system
atrophy and progressive supranuclear palsy. Ann Neurol 1990; 29.
28:547–555.
14. Hoshi H, Kuwabara H, Leger G, et al. 6-[18F]fluoro-L-dopa
metabolism in living human brain: a comparison of six analytical methods. J Cereb Blood Flow Metab 1993;13:57– 69. 30.
15. Snow BJ, Tooyama I, McGeer EG, et al. Human positron
emission tomographic [18F]fluorodopa studies correlate with
dopamine cell count and levels. Ann Neurol 1993;34:324 –330.
16. Fahn S, Elton R, Members of the UPDRS Development Com- 31.
mittee Recent developments in Parkinson's disease. In: Fahn S,
Marsden CD, Calne DB, eds. Recent development in Parkinson's Disease Vol 2. Florham Park, NJ: Macmillan Health Care
32.
Information, 1987:153–163, 293–304.
17. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ.
Parametric imaging of ligand-receptor binding in PET using a
33.
simplified reference region model. Neuroimage 1997;6:
279 –287.
18. Studholme C, Hill DL, Hawkes DJ. Automated threedimensional registration of magnetic resonance and positron
emission tomography brain images by multiresolution optimi- 34.
sation of voxel similarity measures. Med Phys 1997;24:25–35.
19. Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of
spatial normalization of PET ligand images using ligand-specific 35.
templates. Neuroimage 1999;9:545–553.
20. Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal
dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study. Brain 1999;122:1637–1650. 36.
21. Piccini P, Brooks DJ, Bjoerklund A, et al. Dopamine release
from nigral transplants visualized in vivo in a Parkinson's pa- tient. Nat Neurosci 1999;2:1137–1139.
22. Tsukada H, Nishiyama S, Kakiuchi T, et al. Is synaptic dopa-37.
mine concentration the exclusive factor which alters the in vivo
binding of [11C]raclopride?: PET studies combined with mi- crodialysis in conscious monkeys. Brain Res 1999;84:160 –169.
38.
23. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain do- pamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol
Sci 1973;20:415– 455. 39.
24. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of do- pamine in the striatum of patients with idiopathic Parkinson's
disease: pathophysiologic and clinical implications. N Engl 40.
J Med 1988;318:876 – 880.
